Cargando…
COVID-19 vaccines: ethical framework concerning human challenge studies
BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449865/ https://www.ncbi.nlm.nih.gov/pubmed/32851596 http://dx.doi.org/10.1007/s40199-020-00371-8 |
_version_ | 1783574706753896448 |
---|---|
author | Calina, Daniela Hartung, Thomas Docea, Anca Oana Spandidos, Demetrios A. Egorov, Alex M. Shtilman, Michael I. Carvalho, Felix Tsatsakis, Aristidis |
author_facet | Calina, Daniela Hartung, Thomas Docea, Anca Oana Spandidos, Demetrios A. Egorov, Alex M. Shtilman, Michael I. Carvalho, Felix Tsatsakis, Aristidis |
author_sort | Calina, Daniela |
collection | PubMed |
description | BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses. OBJECTIVES: To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, RESULTS: Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika. CONCLUSIONS: One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-7449865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-74498652020-08-27 COVID-19 vaccines: ethical framework concerning human challenge studies Calina, Daniela Hartung, Thomas Docea, Anca Oana Spandidos, Demetrios A. Egorov, Alex M. Shtilman, Michael I. Carvalho, Felix Tsatsakis, Aristidis Daru Short Communication BACKGROUND: The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses. OBJECTIVES: To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing, RESULTS: Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika. CONCLUSIONS: One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives. GRAPHICAL ABSTRACT: [Image: see text] Springer International Publishing 2020-08-27 /pmc/articles/PMC7449865/ /pubmed/32851596 http://dx.doi.org/10.1007/s40199-020-00371-8 Text en © Springer Nature Switzerland AG 2020 |
spellingShingle | Short Communication Calina, Daniela Hartung, Thomas Docea, Anca Oana Spandidos, Demetrios A. Egorov, Alex M. Shtilman, Michael I. Carvalho, Felix Tsatsakis, Aristidis COVID-19 vaccines: ethical framework concerning human challenge studies |
title | COVID-19 vaccines: ethical framework concerning human challenge studies |
title_full | COVID-19 vaccines: ethical framework concerning human challenge studies |
title_fullStr | COVID-19 vaccines: ethical framework concerning human challenge studies |
title_full_unstemmed | COVID-19 vaccines: ethical framework concerning human challenge studies |
title_short | COVID-19 vaccines: ethical framework concerning human challenge studies |
title_sort | covid-19 vaccines: ethical framework concerning human challenge studies |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449865/ https://www.ncbi.nlm.nih.gov/pubmed/32851596 http://dx.doi.org/10.1007/s40199-020-00371-8 |
work_keys_str_mv | AT calinadaniela covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT hartungthomas covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT doceaancaoana covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT spandidosdemetriosa covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT egorovalexm covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT shtilmanmichaeli covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT carvalhofelix covid19vaccinesethicalframeworkconcerninghumanchallengestudies AT tsatsakisaristidis covid19vaccinesethicalframeworkconcerninghumanchallengestudies |